|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.38 USD | -0.48% |
|
-0.48% | -4.16% |
July 2 (Reuters) - The U.S. Department of Justice informed Viatris that it no longer considers Mylan a subject of its antitrust investigation into the generic drug industry, the company said on Tuesday.
Viatris was formed through the merger of Mylan and Pfizer's Upjohn in 2020. (Reporting by Christy Santhosh; Editing by Shilpi Majumdar)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 27.7 USD | -0.47% | +1.02% | 157B | ||
| 10.38 USD | -0.48% | -0.48% | 12.36B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| -4.16% | 12.36B | |
| +54.07% | 809B | |
| +39.06% | 621B | |
| -7.05% | 351B | |
| +15.44% | 319B | |
| +5.72% | 289B | |
| +14.53% | 238B | |
| -0.41% | 221B | |
| +14.53% | 218B | |
| +7.42% | 166B |
VIATRIS INC. 
